| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.05. | Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod | ||
| 15.05. | After Makary departure, CDER chief Tracy Beth Hoeeg likely headed out at FDA: report | ||
| 15.05. | Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast | ||
| 15.05. | SCOTUS temporarily restores telehealth access to abortion pill mifepristone | ||
| 15.05. | As biologics dominate biopharma pipelines, manufacturing hurdles trip up new launches: report | ||
| 15.05. | Health execs persevere in new policy landscape | ||
| 15.05. | BridgeBio Pharma teams with awareness groups to spotlight ATTR-CM's hidden impact on women | ||
| 14.05. | Eli Lilly delivers $50M boost to UNICEF's pediatric health push | ||
| 14.05. | AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda | ||
| 14.05. | Biopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role? | ||
| 14.05. | FDA floats possible approach to repurpose approved drugs under new uses | ||
| 14.05. | Sun recalls US chemotherapy batch, citing glass particle contamination concerns | ||
| 14.05. | Bora snaps up MacroGenics' manufacturing, CDMO operations for up to $127.5M | ||
| 13.05. | BeOne's Venclexta challenger Beqalzi nets FDA approval as first BCL-2 for mantle cell lymphoma | ||
| 13.05. | As Trump arrives in China, Big Pharma CEOs are notably absent | ||
| 13.05. | Haleon tackles sports injuries with latest soccer play | ||
| 13.05. | BeOne Medicines' Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions' | ||
| 13.05. | Takeda, slimming down for 'new era,' plots 4,500 layoffs in latest restructuring drive | ||
| 13.05. | Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies | ||
| 13.05. | Merck KGaA looks to M&A to bolster its 'rather slim' pipeline | ||
| 12.05. | FDA Commissioner Marty Makary to resign, capping turbulent tenure: report | ||
| 12.05. | Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report | ||
| 12.05. | Alkermes' Lumryz hits phase 3 mark in another sleep disorder, fueling momentum from $2.4B Avadel acquisition | ||
| 12.05. | As public vaccine criticism quiets, RFK Jr. keeps safety inquiries running in background: NYT | ||
| 12.05. | Pfizer, Arvinas win $85M upfront in Rigel licensing pact for new breast cancer med Veppanu |